Harvard Bioscience develops and sells scientific instruments, software, and consumables used in life science research, drug development, and preclinical testing. Customers include academic institutions, NIH-funded researchers, pharma and biotech companies, and CROs. The company sells through direct sales (~61% of revenue) and distributors (~39%), including Fisher Scientific for North American distribution, and has operations in the U.S., Europe, and China. Harvard Bioscience organizes products into two segments: Preclinical (~54% of revenue) and Cellular & Molecular (~46%). The Preclinical segment is anchored by implantable telemetry systems sold under the DSI brand, used to monitor cardiovascular, neurological, and metabolic data in live animal models for GLP-compliant drug safety studies. The Cellular & Molecular segment includes electrophysiology instruments, syringe pumps, electroporation devices, and amino acid analyzers. Key growth platforms include MeshMEA (an organoid monitoring system) and BTX electroporation (used for cell transfection in vaccine and CAR-T bioproduction). About 55% of revenue is recurring, coming from consumables, software licenses, and services. In platforms like MeshMEA and BTX, Harvard Bioscience uses a razor-and-blade model where instrument sales drive ongoing consumable revenue. Harvard Bioscience is shifting its positioning toward "translational science," targeting the gap between animal model research and human clinical outcomes, and is investing in organoid and 3D biology platforms as regulatory frameworks increasingly encourage human-derived alternatives to animal testing.